Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)

NCT01534819 · View on ClinicalTrials.gov ↗

Study Summary

The ANCHOR registry is a multi-center, post-market, non-interventional, non-randomized, prospective study. Subjects must sign an ICF prior to obtaining any study specific information. Subjects are eligible to be consented up to 30 days post-procedure. Enrolled subjects will be followed as per local 'standard of care' for up to 5 years post procedure. Study recommended follow-up is per SVS and ESVS guidance.

Conditions Studied

Interventions

  • DEVICE EndoAnchor™
  • PROCEDURE endovascular treament

Study Locations (20)

California

  • VA Loma Linda Medical Center — Loma Linda
  • El Camino Hospital — Mountain View
  • University of California Irvine Medical Center — Torrance
  • Harbor - UCLA Medical Center — Torrance

Florida

  • Baptist Cardiac & Vascular Institute — Miami
  • Florida Hospital — Orlando
  • University of South Florida — Tampa

Illinois

  • HeartCare Midwest — Peoria
  • Evanston Hospital — Skokie
  • Southern Illinois University — Springfield

Maryland

  • University of Maryland Medical Center — Baltimore
  • Johns Hopkins Bayview Medical Center — Baltimore

Alabama

  • University of Alabama — Birmingham

Arizona

  • Abrazo Arizona Heart Institute — Phoenix

Arkansas

  • John L McClellan Memorial Veterans Hospital — Little Rock

Connecticut

  • Yale University School of Medicine — New Haven

Trial Details

FieldValue
Enrollment Target 1,090 participants
Start Date 2012-04
Est. Completion 2026-04-24

Sponsor

Medtronic Cardiovascular

49 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01534819

The ClinicalTrials.gov registry entry for NCT01534819 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,090 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiovascular, which has 49 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Aortic Aneurysm appearing as the primary indexed condition, and to 2 interventions — of which EndoAnchor™ is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT01534819 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT01534819 about?

NCT01534819 is a clinical study titled "ANCHOR (Aneurysm Treatment Using the Heli-FX™ EndoAnchor™ System Global Registry)". The ANCHOR registry is a multi-center, post-market, non-interventional, non-randomized, prospective study. Subjects must sign an ICF prior to obtaining any study specific information. Subjects are eligible to be consented up to 30 days post-procedure. Enrolled subjects will be followed as per loca...

What is the current status of trial NCT01534819?

This trial is currently active not recruiting. The enrollment target is 1,090 participants. The study started on 2012-04. Estimated completion is 2026-04-24.

What conditions does trial NCT01534819 study?

This clinical trial studies the following conditions: Aortic Aneurysm. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT01534819?

The interventions under investigation include: EndoAnchor™ (DEVICE), endovascular treament (PROCEDURE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT01534819?

This trial is sponsored by Medtronic Cardiovascular, which has 49 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT01534819 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial